List of Cell Therapies Companies in Netherlands - 10

AM-Pharma BV is a biopharmaceutical company developing recombinant Alkaline Phosphatase for clinical use.

Amphera is a late-stage biotechnology company developing cell therapies to treat cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.

Cimaas - Our mission is achieving a better cure for cancer. For this, CiMaas develops therapies engaging the immune system for the treatment of a steadily growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking away several of the severe side-effects of current therapies.

We are Erasmus MC. Our roots lie in Rotterdam, a city and port of international standing. We are the most innovative university medical center in the Netherlands and one of the world’s leading centers of scientific research. We are committed to achieving a healthy population and pursuing excellence in healthcare through research and teaching. Day in, day out, our staff, volunteers and students work with passion and dedication to achieve everything we stand for: safe, first-rate healthcare for patients with complex issues, unusual and rare conditions or acute needs. But we also stand for top-quality teaching that attracts ambitious, inquisitive and talented students and seeks to answer the healthcare questions of tomorrow. And we stand for world-class scientific research that bolsters our understanding of diseases and disorders and helps to predict, treat and prevent them. We do our work based on our basic principles, the core values of Erasmus MC, 'responsible'​, 'connecting'​ and 'enterprising'​. We believe that we provide the best care, research and education if we are responsible, binding and enterprising.

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues. We leverage nature's own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery. Welcome to the next frontier of medicine. Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy. We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies. The mission of NTrans Technologies is to become the leading non-viral delivery platform in cell and gene therapy. Please contact us at: info@ntranstechnologies.com

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases. With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.